New imaging study reveals how glaucoma drug works inside the eye

NCT ID NCT07588152

Recruiting now Knowledge-focused Sponsor: Indiana University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study uses special cameras to take detailed pictures of the eye's drainage system in people with glaucoma or high eye pressure. Half of the 50 participants will use Rhopressa eye drops daily for two weeks, while the other half will use artificial tears. The goal is to see if Rhopressa changes the structure of the drainage tissue, which may explain how it lowers eye pressure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Netarsudil ophthalmic solution (Rhopressa)
What this could lead to: If successful, this study could help explain how Rhopressa lowers eye pressure, potentially leading to better treatments for glaucoma.
What could go wrong: This is a small, early-phase imaging study, not a large trial testing long-term outcomes. The results may not directly translate to better patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLAUCOMA OCULAR HYPERTENSION

Contacts and locations

Locations

Indiana Universtiy School of Optometry
RECRUITING

Bloomington, Indiana, 47405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.